Morgan Stanley analyst Bob Huang maintained a Buy rating on Metlife today and set a price target of $97.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bob Huang has given his Buy rating due to a combination of factors that highlight MetLife’s strong performance and resilient business model. The company’s recent earnings report showed significant strength in its US and Asia operations, which were key drivers in surpassing earnings expectations. The US Group Benefits segment experienced a notable turnaround, supported by favorable expense management and business growth, indicating that previous weaknesses were temporary.
Additionally, the Asia segment outperformed expectations with impressive sales growth, particularly in Japan and other Asian markets, driven by new product launches and enhancements. MetLife Holdings also exceeded consensus estimates, further demonstrating the company’s ability to manage investment portfolio risks and maintain earnings stability. Despite some challenges in the corporate segment, the overall positive financial results and the company’s ability to navigate global macro uncertainties contribute to the Buy rating.
According to TipRanks, Huang is an analyst with an average return of -2.5% and a 46.81% success rate. Huang covers the Financial sector, focusing on stocks such as Progressive, Principal Financial, and Accelerant Holdings Class A.
In another report released today, UBS also maintained a Buy rating on the stock with a $95.00 price target.